The first generic GLP-1 medication is already here. In December 2024, the FDA approved a generic version of liraglutide (the active ingredient in Victoza) made by Hikma Pharmaceuticals. But if you’re searching for a generic version of the more popular drugs like Ozempic, Wegovy, or Mounjaro, those are still years away. Semaglutide’s core U.S. patent expires in 2032, and tirzepatide’s doesn’t expire until 2036 at the earliest.
Liraglutide: The First Generic GLP-1
Liraglutide, sold as Victoza for type 2 diabetes, became the first GLP-1 receptor agonist to get generic competition in the United States. The FDA approved Hikma’s generic version on December 23, 2024, for adults and children aged 10 and older with type 2 diabetes. This approval came after Teva had secured a license to launch a generic as early as December 2023 through a patent settlement with Novo Nordisk.
It’s worth noting that this generic is for Victoza, the diabetes formulation. Saxenda, the weight loss version of liraglutide, is a separate product. Generic liraglutide could still put downward pressure on prices in this corner of the GLP-1 market, but it won’t satisfy the millions of people looking for affordable alternatives to semaglutide or tirzepatide.
Semaglutide (Ozempic, Wegovy): 2032 at the Earliest
Novo Nordisk’s U.S. patent on semaglutide is set to expire in 2032. That’s the earliest a generic or biosimilar version of Ozempic or Wegovy could reach the American market, and additional patents or legal challenges could push that date further out. Pharmaceutical companies routinely build layered patent portfolios that extend protection well beyond the original molecule patent.
Outside the U.S., the timeline is different. Novo Nordisk’s semaglutide patent in China expires in 2026, which could make China the first major market to see generic semaglutide. That won’t directly help U.S. consumers, but it signals that global competition is coming sooner than the American patent landscape suggests.
Tirzepatide (Mounjaro, Zepbound): 2036 to 2039
Tirzepatide, the dual-action drug sold as Mounjaro for diabetes and Zepbound for weight loss, has even longer patent protection. The core molecule patent expires in January 2036. However, Eli Lilly holds formulation patents that don’t expire until June 2039, which could block generic manufacturers from producing their own versions for several additional years. Unless those formulation patents are successfully challenged in court, generic tirzepatide is realistically a late-2030s prospect.
Generic vs. Biosimilar: Why It Matters
Not all GLP-1 drugs follow the same regulatory path to generic competition. Some, like liraglutide and semaglutide, were approved as traditional drugs, which means generic manufacturers can use the standard abbreviated approval process. They need to show their product is bioequivalent to the original, a relatively straightforward bar to clear.
Others, like dulaglutide (Trulicity), were regulated as biologics from the start. Biologics are manufactured from living systems like yeast or bacteria rather than synthesized from chemicals. Their copies are called biosimilars rather than generics, and the approval process is more demanding. Biosimilar manufacturers must demonstrate their product is “highly similar” to the original with no clinically meaningful differences in safety or effectiveness. This typically takes longer and costs more to develop, which can delay competition and keep prices higher even after patents expire.
This regulatory distinction means the GLP-1 class won’t see a single wave of generic competition. Each drug will follow its own timeline based on both its patent expiration and its regulatory classification.
What About Compounded Semaglutide?
While people wait for true generics, compounded versions of semaglutide have filled part of the gap. During the national semaglutide shortage, compounding pharmacies were legally permitted to produce their own versions. The FDA has since declared that shortage resolved, and enforcement discretion periods have been winding down. For outsourcing facilities operating under section 503B of federal law, the FDA’s grace period extended until May 22, 2025.
Compounded semaglutide is not FDA-approved. It doesn’t go through the same rigorous review for safety, effectiveness, and quality that branded or generic drugs undergo. With the shortage officially over, compounding pharmacies face legal restrictions on making copies of commercially available drugs. The window for legally obtaining compounded semaglutide is closing, and it was never intended as a permanent alternative to generic competition.
A Quick Timeline Summary
- Liraglutide (Victoza): Generic approved December 2024, available now
- Semaglutide (Ozempic, Wegovy): U.S. patent expires 2032; China patent expires 2026
- Tirzepatide (Mounjaro, Zepbound): Molecule patent expires January 2036; formulation patents extend to June 2039
- Dulaglutide (Trulicity): Regulated as a biologic, requiring the more complex biosimilar pathway; timeline less transparent due to different patent disclosure rules
For most people searching this question, the honest answer is that affordable generic versions of the GLP-1 drugs driving today’s demand are still 7 to 14 years away in the United States. The liraglutide generic is a meaningful first step, but the blockbuster drugs that millions of people associate with this class remain firmly under patent protection for the foreseeable future.